Table 4b.
Summary of findings: Parenteral anticoagulation versus oral anticoagulation be used in cancer patients with central venous catheters.
| Patient or population: Patients with thrombosis prophylaxis in cancer patients with central venous catheters Settings: Outpatient or inpatient Intervention: LMWH Comparison: VKA | |||||
|---|---|---|---|---|---|
| Outcomes | Illustrative comparative risksa (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | |
| Assumed risk VKA |
Corresponding risk LMWH |
||||
|
| |||||
| Death | 87 per 1000 | 96 per 1000 (56––168) | RR 1.11 (0.64–1.93) | 623 (3 studies) | Low |
| Symptomatic DVT | 43 per 1000 | 67 per 1000 (33–137) | RR 1.55 (0.76–3.15) | 560 (3 studies) | Low |
| Major bleeding | 0 per 1000 | 0 per 1000 (0–0) | RR 3.1 (0.13–73.14) | 343 (2 studies) | Low |
| Thrombocytopenia | 202 per 1000 | 346 per 1000 (245–492) | RR 1.71 (1.21–2.43) | 339 (2 studies) | Moderate |
CI, Confidence interval; DVT, deep vein thrombosis; LMWH, low molecular weight heparin; RR, Risk ratio; VKA, vitamin K antagonist.
a
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).